Drug intelligence / Profile preview

VTA-200

Development stage: Preclinical
Lead developer: Vita Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Gene Therapies

Overview

VTA-200 is a genetically engineered, induced pluripotent stem cell (iPSC)-derived cell therapy being developed by Vita Therapeutics. It is intended as a treatment for multiple forms of muscular dystrophy. The development of VTA-200 is supported by a $32 million Series A financing round led by Cambrian Biopharma, with participation from Kiwoom Bio, SCM Life Sciences, and Early Light Ventures, aimed at advancing the program.

Beyond the preview

Go deeper on VTA-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTA-200.